1 CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 U.S. dependent areas—2011. HIV Surveillance Supplemental Report 2013;18(No. 5). Published October 2013.
2 CDC. Estimated HIV incidence in the United States, 2007–2010. HIV Surveillance Supplemental Report 2012;17(No. 4). Published December 2012.
3 Smith MK, Rutstein SE, Powers KA, Fidler S, Miller WC, Eron JJ Jr, Cohen MS. The detection and management of early HIV infection: a clinical and public health emergency. J Acquir Immune Defic Syndr.2013; 63 Suppl 2:S187-99
5 Rietmeijer CA , Kane MS, Simons PZ, et al. Increasing the use of bleach and condoms among injecting drug users in Denver: outcomes of a targeted, community-level HIV prevention program. AIDS 1996;10:291–8.
6 Rhodes F, Malotte CK. HIV risk interventions for active drug users. In: S.Oskamp, S.Thompson, eds. Understanding HIV risk behavior: safer sex and drug use. Thousand Oaks, CA: Sage Publications, 1996:297–36.
7 Gibson DR, Lovelle-Drache J, Young M, Hudes ES, Sorensen JL. Effectiveness of brief counseling in reducing HIV risk behavior in injecting drug users: final results of randomized trials of counseling with and without HIV testing. AIDS and Behavior 1999;3:3–12.
8 Doll LS, O'Malley PM, Pershing AL, Darrow WW, Hessol NA, Lifson AR. High-risk sexual behavior and knowledge of HIV antibody status in the San Francisco City Clinic Cohort. Health Psychol 1990;9:253–65.
11 van Griensven GJP, de Vroome EMM, Tielman RAP, et al. Effect of human immunodeficiency virus (HIV) antibody knowledge on high-risk sexual behavior with steady and nonsteady sexual partners among homosexual men. Am J Epidemiol 1989;129:596–603.
14 Desenclos J-C, Papaevangelou G, Ancelle-Park R, for the European Community Study Group on HIV in Injecting Drug Users. Knowledge of HIV serostatus and preventive behaviour among European injecting drug users. AIDS 1993;7:1371–7.
16 Otten MW Jr, Zaidi AA, Wroten JE, Witte J, Peterman TA. Changes in sexually transmitted disease rates after HIV testing and posttest counseling, Miami, 1988 to 1989. Am J Pub Health 1993;83:529–33.
18 CDC. Cases of HIV infection and AIDS in the United States, 2004. HIV/AIDS Surveillance Report 2005;16:16-45.
20 CDC. HIV prevention practices of primary care physicians—United States, 1992. MMWR 1994;42:988–92.
24 Horton T, Uniyal A, Smith LV, Curreri S, Kerndt P, Branson B. Feasibility of implementing rapid HIV testing in a community-based setting. National HIV Prevention Conference; Atlanta GA; July 2003. Abstract T2-C1503.
25 Luo W, Masciotra S, Delaney KP, Charurat M, Croxton T, Constantine N, et al. Comparison of HIV oral fluid and plasma antibody results during early infection in a longitudinal Nigerian cohort. J Clin Virol, 2013. 58 Suppl 1: e113-8.
26 Masciotra S, Luo W, Youngpairoj AS, Kennedy MS, Wells S, Ambrose K, et al. Performance of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. J Clin Virol, 2013.
- Page last reviewed: November 26, 2014
- Page last updated: February 18, 2015
- Content source: Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention